SomaLogic, Inc. (SLGC) News
Filter SLGC News Items
SLGC News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SLGC News Highlights
- SLGC's 30 day story count now stands at 2.
- Over the past 26 days, the trend for SLGC's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- EAC, LAB and NOV are the most mentioned tickers in articles about SLGC.
Latest SLGC News From Around the Web
Below are the latest news stories about SOMALOGIC INC that investors may wish to consider to help them evaluate SLGC as an investment opportunity.
Standard BioTools and SomaLogic Announce Date for Special Meetings of Stockholders to Vote on Proposed MergerSOUTH SAN FRANCISCO, Calif. and BOULDER, Colo., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – and SomaLogic, Inc. (Nasdaq: SLGC), a leader in data-driven proteomics technology, today announced that the companies have set a date for their respective Special Meetings of Stockholders in connection with the pending all-stock merger which was previously announced on October 4, 2023. Eac |
SomaLogic Reports Recent Business Highlights and Third Quarter 2023 Financial ResultsRevenue of $22.0 million, reflecting 14% year-over-year growth when excluding royalty revenue from NEB in the corresponding prior-year periodCash and investments of over $450 millionRaising full year 2023 revenue guidance to $82 million to $85 millionManagement to host conference call today at 4:30pm ET BOULDER, Colo., Nov. 08, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today reported recent business highlights and financial results for the quarter ended Septemb |
SomaLogic announces new SomaScan® 11K PlatformExpanded menu gives researchers broadest coverage of the proteome for increased discovery of biomarkers and drug targetsBOULDER, Colo., Nov. 01, 2023 (GLOBE NEWSWIRE) -- SomaLogic Inc., (Nasdaq:SLGC), a leader in data-driven proteomics technology, today announced the launch of its high-plex proteomics platform, which provides 11,000 total protein measurements. The SomaScan 11K Platform is the largest proteomics offering available on the market. The new high-plex platform is expected to give rese |
SomaLogic to Announce Third Quarter 2023 Financial Results on November 8, 2023BOULDER, Colo., Oct. 31, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that it will report financial results for the third quarter 2023 after market close on November 8, 2023. Management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Those interested in listening to the conference call should register online here. Participants are encouraged to register more than 15 minutes before the start of the call. A live and arc |
Standard BioTools and SomaLogic to Combine in All-Stock Merger Creating a Diversified Leader in Life Sciences ToolsActivates Standard BioTools’ strategy to unlock value in underserved portion of $100 billion industry Establishes leading platform of multi-omic technologies with the highest throughput and highest data quality to power clinical research insights Expands commercial reach with substantial cross-selling opportunities and complementary offerings Generates estimated $80 million of annual cost synergies by 2026 and enhanced combined path to profitability1 Estimated combined cash of over $500 million |
SomaLogic and Korea’s DNA Link partner to bring the 7,000-plex SomaScan® platform to the fast-growing Asia-Pacific proteomics marketDNA Link will bring the power of the largest proteomics platform available to their biomarker discovery and drug development workBOULDER, Colo. and SEOUL, Korea, Sept. 19, 2023 (GLOBE NEWSWIRE) -- SomaLogic Inc., (Nasdaq:SLGC), a leader in data-driven proteomics technology, today announced its partnership with DNA Link, an innovator in personalized and precision medicine, to offer the 7,000-plex SomaScan® platform to their customers. DNA Link will be the first SomaLogic authorized site in Korea. |
SomaLogic researchers identify key proteins to aid in early detection of lung, colon and breast cancer and ovarian tumorsSomaLogic’s SomaScan® platform was used to target 15 markers shared among all cancer types.BOULDER, Colo., Sept. 12, 2023 (GLOBE NEWSWIRE) -- In a new paper published in Nature's Scientific Reports, researchers at SomaLogic Inc. studied the value of protein biomarkers in the early detection of cancer and the stratification of cancerous tumors. The research team identified 15 blood proteins shared among all cancer types as well as models to stratify tumor types. The goal of this research was to i |
SomaLogic expands agreement with Novo Nordisk to 2025Novo Nordisk will extend its use of SomaLogic’s innovative proteomics technologies for research in cardiometabolic and other diseasesBOULDER, Colo., Sept. 05, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, announced today that it is extending its collaborative agreement with global healthcare innovator, Novo Nordisk. As part of the agreement, which now extends into the end of 2025, Novo Nordisk will expand its use of the SomaScan® proteomics platform in drug researc |
SomaLogic, Inc. (NASDAQ:SLGC) Just Reported Earnings, And Analysts Cut Their Target PriceSomaLogic, Inc. ( NASDAQ:SLGC ) just released its quarterly report and things are looking bullish. Revenues and losses... |
SomaLogic Reports Second Quarter 2023 Financial ResultsRevenue of $20.5 million, an increase of 45% year-over-yearCash and investments of approximately $474 million, a strong capital position to fund current and future business initiativesReiterating full year 2023 revenue guidance and operating expense targetManagement to host conference call today at 4:30pm ET BOULDER, Colo., Aug. 14, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today reported financial results for the quarter ended June 30, 2023. “Our second quarte |